a.s.r. de nederlandse verzekerings maatschappij voor alle verzekeringen

Proposed € 200 million Restricted Tier 1 issuance

Investor Presentation

Chris Figee, CFO

September 2019




Agenda

- Recap H1 2019 results
- Proposed Transaction: Description & Rationale
- New-Issue: Summary Terms
- Consent Solicitation

Key take-aways H1 2019 results

- Strong performance, record operating result in H1 2019
- Solid progress in executing our strategy
- Strong balance sheet, robust high quality solvency with ample financial flexibility
- Well positioned to pursue profitable growth

Solvency II: quality of balance sheet





- Solvency II ratio 191% based on standard formula¹
- Unrestricted Tier 1 capital at € 5,505m: 73% of total own funds and 139% of SCR
- Ample headroom available within SII framework:
 - RT1: € 848m
 - T2 & T3: € 462m
- No use of Tier 3 capacity


- 1. Excluding a.s.r. bank and a.s.r. asset management
- 2. Based on market value
- Including the Grandfathered Tier 1s to be called in September and October 2019
- 4. Presented is the IFRS value, the nominal value is € 209 million


Strong balance sheet with ample financial flexibility

Pro-forma includes the € 200m RT1 tap and the call of the two Grandfathered Tier 1 instruments









Proposed Transaction: Description & Rationale

- New issue of €200m Restricted Tier 1
 - terms to be the same as a.s.r's €300m 4.625% Perpetual-NC-2027 issue (the "Existing RT1")
 - intention is for new issue to become fungible with Existing RT1
- Concurrent consent solicitation seeking permission from holders of Existing RT1 for inclusion of "Further Issues" clause
 - Further Issues clause is required for the new issue to become fungible with the Existing RT1
- a.s.r's intention is to consolidate the new-issue with the Existing RT1, creating a single tranche of €500m, which provides a more liquid benchmark RT1 issue for the benefit of both Existing RT1 holders and participants in the new-issue

Capital Optimisation

- Redemption of €209m outstanding Tier 1 instruments already announced¹
- No explicit need for capital replacement
- Prudent optimisation of balance sheet, comfortably within leverage target, whilst protecting hybrid headroom

Increase of Outstanding 4.625% RT1 Issue

- Intention for new tranche to be issued as an increase/tap of a.s.r's €300m RT1 which was issued in 2017
- Acknowledgement of investor preference for larger tranche size
- Improved liquidity as tranche increases to benchmark size €500m from €300m

Consent Solicitation

- Existing RT1 terms do not feature a "Further Issues" provision, which is needed for fungibility
- Consent Solicitation seeks permission from existing holders to add Further Issues clause
- Consent fee of 0.05% for holders who vote in-favour during the first 2 weeks

C.S.T. RESTRICTED 6

¹ See also the press release of 29 August 2019, (https://www.asrnl.com/-/media/files/asrnederland-nl/nieuws-en-pers/2019/20190829-press-release-asr-gt1-725-percent-and-10-percent-redemption.pdf?la=en)

New-Issue: Summary Terms

Issuer	ASR Nederland N.V.
Issue Date	September 2019
Size	EUR 200,000,000 (expected to be fungible with Existing RT1, subject to consent solicitation)
Issue Ratings (M/S/F)	- / [BB+] expected / -
Maturity	Perpetual-NC2027 (Perp-NC8)
First Call Date	19 October 2027
Interest Rate	4.625% until the First Call Date Thereafter reset to 5y Mid-Swap + 3.789%
Non-Payment of Interest	Fully discretionary and cancellable at any time Mandatory cancellation upon breach of SCR or MCR, issuer not being solvent, insufficient distributable items or if otherwise required by the regulator or relevant rules
Arrears of Interest	Non-cumulative
Issuer Call Frequency	First Call Date and every Interest Payment Date thereafter
Redemption Suspension	Upon breach of SCR or MCR, issuer not being solvent, Insolvent Insurer Winding-up or regulatory consent not obtained
Special Event Redemption	Permitted upon a Tax Event, CDE or RME (any time); subject to replacement with equal or better quality capital if prior to year 3, and SCR being exceeded by an appropriate margin if between years 3 and 8
Substitution/Variation	Permitted at any time upon a CDE or RME
Principal Loss Absorption	Full permanent share conversion upon a Trigger Event (Fixed conversion price set at €23.10) Optional Shareholder/third party Offer mechanism at a price no lower than the Current Market Price on Conversion Date
Change in terms on COC	Upon occurrence of Trigger Event, amendments to terms in COC depending on whether the ordinary share capital of the acquirer is listed and admitted to trading; could include principal write-down loss absorption instead of conversion to equity
Governing Law	Dutch law
Listing	Irish GEM

 New issue terms identical in all material aspects to Existing 4.625% RT1 notes

√ Call Dates

 Perpetual NC8 structure aligns with Existing RT1 (1st call on 19-Oct-2027)

√ Tax Deductibility Event

- a.s.r. has publicly stated¹ that it has no intention to execute an early redemption of the Existing RT1 as a result of the enacted change in tax treatment by the Dutch tax authorities
- Intention is for new-issue to become fungible with Existing RT1 issue
- Consent Solicitation has been launched in order to facilitate legal fungibility

Note: Indicative only, summary terms should be read in conjunction with the full Offering Circular 1. a.s.r. press release July 6th 2018

C.S.T. RESTRICTED 7

Consent Solicitation¹

- Existing RT1 terms do not include a "Further Issues" provision; such a provision is commonly included in many debt issues; the provision may be included by amending the terms of the Existing RT1 via a Consent Solicitation
- Further issues: The Issuer may from time to time without the consent of the holders of the Securities create and issue further securities, having terms and conditions the same as those of the Securities, or the same except for the amount of the first payment of interest, which may be consolidated and form a single series with the outstanding Securities. The Securities may also be consolidated and form a single series with other securities that the Issuer has issued, having terms and conditions the same as those of the Securities, or the same except for the amounts of the payments of interest already made
- Inclusion of the Further Issues provision will allow for legal fungibility of the new issue with the Existing RT1, ie. same ISIN code
- A consent fee of 0.05% will be payable to holders of the Existing RT1 who vote in favour of the consent solicitation before the early participation deadline
- Noteholder meeting expected to occur on 8 October 2019, results to be published as soon as practicable thereafter
- New-issue to become fungible after the new-issue has been settled, provided that the Consent Solicitation has passed Note: aside from the proposed EUR200m tap, a.s.r. does not intend to conduct any further such increases of the notional amount

^{1.} This summary is qualified by reference to the Consent Solicitation Memorandum, a copy of which security holders may obtain from the Tabulation Agent. Email: xchange.offer@db.com

Disclaimer

- This presentation has been prepared and issued by ASR Nederland N.V. ("ASR Nederland" or the "Company"). For the purposes of this notice, the presentation (the "Presentation") shall mean and include the slides above, the oral presentation of the slides by the Company, the question-and-answer session that follows that oral presentation, hard copies of this document and any materials distributed at, or in connection with, that presentation. The Presentation is strictly confidential and is provided to you solely for your reference. By listening to the (pre-recorded) Presentation or attending the meeting where the Presentation is made, or by reading the Presentation slides, you agree to be bound by the following conditions and acknowledge that you understand the legal and regulatory sanctions attached to the misuse, disclosure or improper circulation of the Presentation.
- No action has been taken by the Company that would permit an offer of securities or the possession or distribution of this Presentation or any other offering or publicity material relating to such securities in any jurisdiction where action for that purpose is required. The release, publication or distribution of this Presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which they are released, published or distributed, should inform themselves about, and observe, such restrictions. This Presentation is not for release, distribution or publication, whether directly or indirectly and whether in whole or in part, into or in the United States or any (other) jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. The Presentation is for information purposes only and are not intended to constitute, and should not be construed as. an offering document, an offer to sell or a solicitation of any offer to buy any securities of the Company described in the Presentation (any such securities, the "Notes") in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of such jurisdiction.
- This Presentation does not constitute a prospectus or an offering circular. This Presentation does not constitute an offer to sell or the solicitation of an offer to buy any Notes or other securities of ASR Nederland. It is an advertisement and does not comprise a prospectus for the purposes of Regulation (EU) 2017/1129 (the "Prospectus Regulation") or otherwise. No reliance may or should be placed for any purposes whatsoever on the information contained in this Presentation or any other material discussed at the Presentation, or on its completeness, accuracy or fairness. The information and opinions contained in this Presentation is provided as at the date of this Presentation and is subject to change without notice. No person is under any obligation to update, complete, revise or keep current the information contained in the Presentation. In relation to any Notes, an offering circular (the "Offering Circular") in preliminary form will be made available. The Offering Circular has been prepared on the basis that all offers of Notes will be made pursuant to an exemption under article 3 of the Prospectus Regulation from the requirement to produce a prospectus for offers of the Notes. The definitive terms of the transactions described therein will be described in the final version of the Offering Circular. Investors should not subscribe for any Notes referred to herein except on the basis of information contained in the Offering Circular. Investors may obtain a copy of the final version of the Offering Circular from ASR Nederland's website (www.asrnl.com).
- This Presentation has not been approved by any regulatory authority. No
 responsibility, obligation or liability (whether direct or indirect, in contract, tort or
 otherwise) is or will be accepted in relation to the Presentation by the Company or
 the Company's subsidiaries or associated companies, or by ABN AMRO Bank N.V.,
 HSBC Bank plc and UBS AG London Branch (the "Joint Lead Managers"), or any
 of their respective directors, officers, employees, advisers or agents.

Continued on next page

Q.S.Y. RESTRICTED 9

Disclaimer

Continued from previous page

- The information contained in the Presentation has not been independently verified. This Presentation includes market share and industry data from industry publications and surveys. The Company and the Joint Lead Managers may not have access to the facts and assumptions underlying the numerical data, market data and other information extracted from publicly available sources and, as a result, these parties are not able to verify such numerical data, market data and other information and do not assume responsibility for the correctness of any market share or industry data or other information included in the Presentation.
- No representation or warranty, express or implied, is made as to the truth, fullness, accuracy, reasonableness or completeness of the information contained herein (or whether any information has been omitted from the Presentation) or any other information relating to the Company, the Company's subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available by the Company or the Joint Lead Managers or any of their respective directors, officers, employees, advisers or agents. Neither the Joint Lead Managers nor any of its directors, officers, employees, advisers or agents accepts any liability for any loss howsoever arising, directly or indirectly, from any use of this Presentation or its contents or otherwise arising in connection therewith. The Joint Lead Managers and its affiliates are acting exclusively for the Company and no one else in connection with the matters referred to in the Presentation and will not regard any other person as their respective clients in relation to such matters and will not be responsible to any other person for providing the protections afforded to their respective clients, or for providing advice in relation to such matters. The Notes are not and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") and will also not be registered with any authority competent with respect to securities in any state or other jurisdiction of the United States of America. The Notes may not be offered or sold in the United States

- of America absent registration or an applicable exemption from the registration requirements under the U.S. Securities Act. There will be no public offering of Notes in the United States.
- This Presentation is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, failing within Article 49(2)(a) to (d) of such Order (all such persons together being referred to as "relevant persons"). Any investment activity to which this communication may relate is only available to, and any invitation, offer, or agreement to engage in such investment activity will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this Presentation or any of its contents. The information in this presentation is given in confidence and the recipients of this presentation should not engage in any behaviour in relation to qualifying investments or related investments (as defined in the Financial Services and Markets Act 2000 ("FSMA") and the Code of Market Conduct made pursuant to FSMA) which would or might amount to market abuse for the purposes of FSMA.
- The Notes are complex financial instruments and are not a suitable or appropriate investment for all investors. The Notes are not intended to be sold and must not be sold to retail clients in the European Economic Area, as defined in the UK Financial Conduct Authority published the Product Intervention (Contingent Convertible Instruments and Mutual Society Shares) Instrument 2015 (the "PI Instrument"). Furthermore, the identified target market for the Notes (for the purposes of the product governance obligations in Directive 2014/65/EC (as amended, "MiFID II")) is eligible counterparties and professional clients; and no key information document ("KID") under Regulation (EU) No 1286/2014 ("PRIIPs") has been prepared and therefore offering or selling the Notes or otherwise making them available to any retail investor in the EEA may be unlawful under PRIIPs.

C.S.T. RESTRICTED 10